PreserVision, Biotrue Brands Help Bausch US Consumer Health See Turnaround More Clearly

Bausch + Lomb’s PreserVision supplement sales grew 17% in Q3, driving 11% growth its US consumer health business. CEO Joseph Papa says Bausch is “making great progress and expect the internal organization design” of its planned spin-off of Bausch + Lomb to be completed in a year.

US sales of its PreserVision eye supplement line grew 17% to help Bausch + Lomb's consumer business show 1% global growth in Q3.

Bausch Health Companies Inc.’s consumer health business is a “recovery in progress” as US revenues grew 11% on sales of eye drops and vision care supplements to push its global results up 1% in the third quarter to $374m.

The Laval, Quebec-based firm’s Bausch + Lomb Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business